Part 4: Pfizer FOIA Document – Feb 28, 2021

This is Part 4 of a 9-part series showcasing the evidentiary findings related to the official Renz Law COVID-19 investigation.

In Part 4, we are introduced to the Pfizer – Cumulative Analysis of Post-Authorization Adverse Event Reports. This Pfizer analysis discusses post emergency authorization adverse event reports and is dated April 30, 2021. The dates covered in the analysis only cover through February 28, 2021. This means the adverse events included only cover about 2.5 months of general availability and only Pfizer products.

Share now!

You cannot copy content of this page